TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program (Seeking Alpha)

TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program

TeamedOn International, Inc., a biotechnology company dedicated to advancing gene therapies for rare diseases, including ophthalmic indications, and UF startup Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced a licensing agreement to advance gene therapy to treat X-linked retinoschisis (XLRS), an inherited disease that causes loss of vision due to degeneration of the retina in males.

Under the terms of the agreement, UF Innovate | Sid Martin Biotech graduate AGTC will provide TeamedOn with the clinical trial material, pre-clinical and clinical data generated for the development of its investigational intravitreal gene therapy candidate, rAAV2tYF-CB-hRS1.

“The license between AGTC and TeamedOn re-opens the possibility of a much-needed treatment for individuals with XLRS,” said Peter Mu, CEO of TeamedOn. “TeamedOn is very pleased to be able to build on AGTC’s efforts, carry on their investment in XLRS to bring potential benefit to patients.”

Read more about TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program.